Nuvectis Pharma, Inc.
NVCT
$11.04
-$1.41-11.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.80% | 35.96% | 16.71% | 8.48% | -5.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.48% | 38.93% | 37.07% | 9.06% | -5.29% |
| Operating Income | -34.48% | -38.93% | -37.07% | -9.06% | 5.29% |
| Income Before Tax | -34.72% | -39.17% | -30.98% | -4.57% | 9.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.72% | -39.17% | -30.98% | -4.57% | 9.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.72% | -39.17% | -30.98% | -4.57% | 9.92% |
| EBIT | -34.48% | -38.93% | -37.07% | -9.06% | 5.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -16.33% | -18.78% | -16.11% | 10.19% | 19.95% |
| Normalized Basic EPS | -6.81% | -9.12% | -12.91% | 5.66% | 16.25% |
| EPS Diluted | -16.33% | -18.78% | -16.11% | 10.19% | 19.95% |
| Normalized Diluted EPS | -6.81% | -9.12% | -12.91% | 5.66% | 16.25% |
| Average Basic Shares Outstanding | 26.27% | 27.42% | 22.26% | 16.01% | 12.15% |
| Average Diluted Shares Outstanding | 26.27% | 27.42% | 22.26% | 16.01% | 12.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |